Biomarker testing is driving a new standard of care
Backed by leading cancer research and advocacy organizations, the Clear Your View initiative aims to ensure complete biomarker testing informs treatment decisions for every advanced cancer patient.
Use results to determine the best treatment plan
New targeted therapies are extending survival for patients with advanced cancers
Patients with targetable alterations respond better to targeted therapy than immunotherapy1
Incomplete testing can lead to sub-optimal patient outcomes
Targeted Therapy
50-83%
Response Rates
Immunotherapy
4-26%
Response Rates
Overall Response, Targeted Therapy vs. Immunotherapy
60%
of CRC patients have a mutation that means anti-EGFRs will not work to treat their disease8
72% of advanced CRC patients who received anti-EGFR therapy did not have RAS and BRAF testing8
Your colleagues have committed to a clear view ahead for every advanced cancer patient
Roadmap to complete biomarker testing
STOP
Test every patient for all recommended biomarkers
WAIT
for complete biomarker results
TREAT
with the best possible therapies
Community oncologists are committed to complete biomarker testing
Growing patient awareness
A thriving community of patient organizations advocate for complete testing before treatment